Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 472

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Mechanism of biological synergy between cellular Src and epidermal growth factor receptor

Open access
Tice, David A., Biscardi, Jacqueline S., Nickles, Amanda L., Parsons, Sarah J. · 1999 · Proceedings of the National Academy of Sciences

Abstract

Overexpression of both cellular Src (c-Src) and the epidermal growth factor receptor (EGFR) occurs in many of the same human tumors, suggesting that they may functionally interact and contribute to the progression of cancer. Indeed, in murine fibroblasts, overexpression of c-Src has been shown to potentiate the mitogenic and tumorigenic capacity of the overexpressed EGFR. Potentiation correlated with the ability of c-Src to physically associate with the activated EGFR and the appearance of two unique in vivo phosphorylations on the receptor (Tyr-845 and Tyr-1101). Using stable cell lines of C3H10T½ murine fibroblasts that contain kinase-deficient (K−) c-Src and overexpressed wild-type EGFR, we show that the kinase activity of c-Src is required for both the biological synergy with the receptor and the phosphorylations on the receptor, but not for the association of c-Src with the receptor. In transient transfection assays, not only epidermal growth factor but also serum- and lysophosphatidic acid-induced DNA synthesis was ablated in a dominant-negative fashion by a Y845F mutant of the EGFR, indicating that c-Src-induced phosphorylation of Y845 is critical for the mitogenic response to both the EGFR and a G protein-coupled receptor (lysophosphatidic acid receptor). Unexpectedly, the Y845F mutant EGFR was found to retain its full kinase activity and its ability to activate the adapter protein SHC and extracellular signal-regulated kinase ERK2 in response to EGF, demonstrating that the mitogenic pathway involving phosphorylation of Y845 is independent of ERK2-activation. The application of these findings to the development of novel therapeutics for human cancers that overexpress c-Src and EGFR is discussed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.96.4.1415

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 4

  1. A E Ottenhoff-Kalff, G Rijksen, E A van Beurden, A Hennipman, A A Michels, G E Staal Cancer Res 52, 4773–4778 (1992).
  2. Biscardi J. S. Tice D. A. & Parsons S. J. (1999) Adv. Cancer Res. 76 in press.
  3. 10.1128/mcb.11.9.4698-4709.1991 · doi:10.1128/mcb.11.9.4698-4709.1991
  4. E Vigna, L Naldini, L Tamagnone, P Longati, A Bardelli, F Maina, C Ponzetto, P M Comoglio Cell Mol Biol 40, 597–604 (1994).

Cited by

See all 472

Metadata

Authors
Tice, D. A., Biscardi, J. S., Nickles, A. L., & Parsons, S. J.
Venue
Proceedings of the National Academy of Sciences
Published
1999-02-16
Volume
96
Issue
4
Pages
1415-1420
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2076718022
Cited by
472
References
33
FWCI
7.21
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.